Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain

• 2024

  Sign in to bookmark this resource.

  Sign in
• Jorge Mestre-Ferrándiz; Agustín Rivero; Alejandro Orrico-Sánchez; Álvaro Hidalgo; Fernando Abdalla; Isabel Martín
PMID: 38238680DOI: https://dx.doi.org/10.1186/s12879-024-08988-9

---

Access Resources

• Journal ArticleEN

About

Respiratory syncytial virus (RSV) is a serious disease with high social and economic costs. New preventive options like nirsevimab are being considered. This study developed a decision analysis framework to compare nirsevimab with a placebo for preventing RSV in newborns and infants in Spain. Experts concluded that nirsevimab could effectively prevent RSV, reduce hospital visits, promote public health awareness, and improve healthcare equality in Spain. Nirsevimab appears to be a promising preventive measure against RSV for newborns and infants in Spain.

---

Tags

Hazard: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Decision Support Techniques; Infant; Infant, Newborn; Respiratory Syncytial Virus Infections; Spain; Respiratory Syncytial Virus, Human; Antibodies, Monoclonal, Humanized

Institutions: University Carlos III; BioMad; Fisabio-Public Health; Catholic University of Valencia; Instituto de Salud Carlos III; Weber Foundation

---

More like this

Assessment of Effectiveness and Impact of Universal Prophylaxis With Nirsevimab for Prevention of Hospitalizations Due to Respiratory Syncytial Virus in Infants. The NIRSE-GAL Study Protocol 2024 · Instituto de Investigación Sanitaria, World Health Organization (WHO), University of Santiago de Compostela, Instituto de Salud Carlos III Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions 2024 · University Medical Center Utrecht, Respiratory Syncytial Virus NETwork (ReSViNET) Foundation Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting. 2024 · Fisabio-Public Health, Instituto de Salud Carlos III, University of Valencia

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---